“We also anticipate meaningful readouts this year for POTS and LRx.”

In context

“ur key oncology programs, we aim to bring forward what could represent the first potential treatment advancement in more than thirty years for patients with BCG-naive high-risk non-muscle invasive bladder cancer. We are encouraged by a positive result of the pivotal phase three CREST trial of sarsallima in combination with BCG, a current standard of care. We presented the full data from this study this past weekend at the annual meeting of the America Neurological Association. Non-muscle invasive bladder cancer is a condition predominantly treated by urologists. In multiple market research and focus group studies, urologists stated a significant preference for a subcutaneous PDL1 because it can be used in their practices and eliminates the need to refer their patients to infusion centers. We also anticipate meaningful readouts this year for POTS and LRx. PADCER plus pembrolizumab is the most prescribed first-line treatment for locally advanced metastatic urothelial cancer in the US. We are working to more than double the total addressable patient population in the US for parts with potentially registrational interim data we expect this year from ongoing pivotal studies in muscle-invasive bladder outcomes. We are also working to reach a significantly expanded population of patients with multiple myeloma. We are anticipating a phase two readout this year for LRxview in a study for double-class exposed relapsed refractory multiple myeloma. If successful and approved, this would more than double the addressable population versus the currently approved indication. In addition to the increased addressable population, moving to earlier lines of”